Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research

This page shows the latest Cancer Research news and features for those working in and with pharma, biotech and healthcare.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .

Latest news

More from news
Approximately 23 fully matching, plus 357 partially matching documents found.

Latest Intelligence

  • Well-funded life sciences firms are making long-term progress – and their investors are too Well-funded life sciences firms are making long-term progress – and their investors are too

    Avacta can have transformative effects in the fight against cancer research. ... antigen test for population screening using Affimer reagents that bind to the SARS-CoV-2 spike protein, but also accelerate and expand work on their pre| CISION pipeline of

  • Can digital communications boost behaviour change? Can digital communications boost behaviour change?

    Using a ‘one-size-fits-all’ approach can result in poor uptake or even backlash, such as Cancer Research UK being accused of fat-shaming while trying to raise awareness of ... the link between obesity and cancer.

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In 2015 the EUROCARE-5 study – the biggest collaborative research project on cancer survival in Europe – showed that between 2000 and 2007, 5-year

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    Living to tell the tale. Having worked in cancer research 20 years ago, I recall there was often a feeling across the field that we had hit a brick wall and ... To advance Alzheimer’s research, I believe that there are similar lessons to learn from the

  • Building Europe’s next breakthrough biotechs Building Europe’s next breakthrough biotechs

    Its founding investors include Cambridge Innovation Capital, Babraham Research Campus through Babraham Bioscience Technologies, Roche's biotech arm Genentech, and Dr Jonathan Milner and Dr Ian Tomlinson, two of the ... life sciences campus in central

More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest appointments

  • McCann Health France strengthens team with two new hires McCann Health France strengthens team with two new hires

    Initially, she worked on the research and development of new drugs in cardiovascular and metabolic diseases before specialising in oncology and onco-haematology. ... Prior to McCann Health France, she served as scientific director at various

  • F-star hires ex-BMS immuno-oncology leader

    pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... Association for Cancer Research.

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from

More from appointments
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 35 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....